Dyadic International (DYAI) Stock Price, News & Analysis

Dyadic International, Inc. (doing business as Dyadic Applied BioSolutions) is a global biotechnology company that uses proprietary microbial platforms to produce recombinant, animal-free proteins and enzymes for non-therapeutic applications. According to company disclosures, Dyadic focuses on high-value, precision‑engineered functional input proteins used across life sciences, food and nutrition, and bio‑industrial markets. The company’s common stock trades on the Nasdaq Capital Market under the symbol DYAI.

Dyadic’s business centers on its patented and proprietary C1 and Dapibus™ microbial gene expression platforms. These platforms are used to produce recombinant proteins that are either sold directly, supplied through partners, or licensed under commercial agreements. Company materials state that these platforms are intended to support flexible, cost‑effective manufacturing and form the foundation of a growing portfolio of commercial and partnered programs across multiple sectors.

Business focus and operating model

Dyadic describes itself as a biotechnology company focused on the scalable production of functional input proteins rather than finished therapeutics. Its proteins are used in areas such as non‑animal cell culture media, molecular biology reagents, nutrition ingredients, and industrial bioprocessing. The company reports that it has transitioned from being primarily research and development‑driven to a more commercially focused organization, emphasizing revenue from product sales, licenses, milestones, and grants.

In life sciences, Dyadic is advancing recombinant proteins for serum‑free cell culture media and related applications. Company updates highlight programs in recombinant serum albumin, recombinant transferrin, and recombinant growth factors such as Fibroblast Growth Factor (FGF) for use in research, diagnostics, cultured meat, and broader life sciences biomanufacturing. Dyadic also reports developing DNA/RNA manipulation enzymes, including RNase‑free DNase‑1, RNase inhibitors, and T7 RNA polymerase for molecular diagnostics, biopharma, and research markets.

Food and nutrition applications

Dyadic is also active in non‑animal dairy and nutrition proteins. Company communications describe development and commercialization efforts around recombinant alpha‑lactalbumin and human lactoferrin, targeting infant nutrition, healthy aging, medical nutrition, and research markets. Through a Development and Commercialization Agreement with BRIG BIO, Dyadic is working on animal‑free bovine alpha‑lactalbumin produced using the Dapibus™ fungal expression system, with BRIG BIO funding development and receiving a global commercial license to production strains, while Dyadic participates in milestone payments, revenue sharing, and co‑marketing.

Dyadic also reports a collaboration with Inzymes ApS on non‑animal dairy enzymes, under which it has achieved productivity milestones and received milestone payments. These enzymes are being scaled toward commercial launch for food and nutrition applications, with additional enzyme candidates under development.

Bio‑industrial and bio‑based products

In the bio‑industrial segment, Dyadic has partnered with Fermbox Bio to develop and commercialize EN3ZYME™, an enzyme cocktail produced on the Dapibus™ platform for converting agricultural residue into fermentable cellulosic sugars. Company disclosures state that initial enzyme deliveries have been completed under Fermbox purchase orders and that Dyadic expects to receive a 50/50 profit share from commercial sales. Sampling and business development efforts are reported in biomass processing, biofuels, pulp and paper, and related markets.

An expanded strategic collaboration with Fermbox Bio allows Fermbox to manufacture and commercialize an expanding portfolio of Dyadic‑developed proteins and enzymes using both the C1 and Dapibus™ expression systems. Under this collaboration, Dyadic and Fermbox can dual‑source production strains and finished products, integrate Fermbox‑developed products into a joint portfolio, and manage a shared, continuously updated product pipeline of fermentation‑derived biomolecules for life science, food and nutrition, and bio‑industrial markets.

Life sciences tools and cell culture media

Dyadic reports several specific life sciences programs:

• Recombinant serum albumin (with Proliant Health and Biologicals) for use in cell culture, diagnostics, and vaccine stabilization, where Dyadic has received multiple milestone payments and anticipates revenue sharing from commercial sales.
• Recombinant transferrin, described as an animal‑free alternative to serum‑derived transferrin, with performance comparable to leading recombinant standards in cell proliferation testing for animal muscle cell growth, targeting applications in cell culture media, diagnostics, research, and bioprocessing.
• Recombinant growth factors such as FGF, which the company states have shown comparable efficacy to reference standards in supporting animal muscle cell growth, with ongoing optimization and validation.
• DNase‑1 (RNase‑free), where Dyadic has completed production validation and is manufacturing research‑grade material for molecular diagnostics, biopharma, and related applications, with sampling underway.
• An expanded nucleic acid enzyme portfolio, including RNase inhibitors and T7 RNA polymerase, with prototype development and validation in progress.

Biopharmaceutical platform collaborations

Although Dyadic’s commercial focus is on non‑therapeutic applications, its C1 platform is also being evaluated in multiple grant‑funded vaccine and antibody programs. Company releases describe collaborations supported by organizations such as the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations (CEPI). These programs assess the C1 platform for producing monoclonal antibodies against diseases such as malaria and RSV, and for manufacturing recombinant protein vaccines and filovirus vaccine candidates. Dyadic reports that C1‑produced monoclonal antibodies have shown performance comparable to those produced in traditional CHO cell lines in early studies.

Dyadic also notes participation in the European Vaccines Hub, an EU‑backed initiative evaluating technologies that could accelerate vaccine R&D and manufacturing. In addition, collaborations with partners such as Uvax Bio and the AdaptVac consortium are assessing the C1 platform for rapid, cost‑efficient vaccine antigen production.

Genetic engineering and technology platform

To enhance its microbial platforms, Dyadic has entered into a CRISPR/Cas9 license agreement with ERS Genomics. This agreement grants access to ERS’s CRISPR/Cas9 patent portfolio and is intended to expand Dyadic’s genetic engineering toolkit. Company statements indicate that integrating CRISPR‑based gene editing into its workflows is expected to support faster strain engineering, pathway optimization, and improvements in productivity and product quality across both the C1 and Dapibus™ platforms.

Dyadic’s C1 platform is based on the Thermothelomyces heterothallica fungus, historically referred to by the company as C1. Earlier descriptions also note that Dyadic has licensed aspects of this technology to third parties for industrial (non‑pharmaceutical) applications. The company continues to position C1 and Dapibus™ as core assets for partners seeking scalable microbial production of recombinant proteins.

Commercial strategy and partnerships

Recent updates emphasize Dyadic’s shift toward commercial execution. The company has rebranded as Dyadic Applied BioSolutions, redesigned its corporate website to prioritize commercial engagement, and reports expanding online ordering capabilities for research products. Dyadic highlights a growing network of commercial and development partners across regions and sectors, including Proliant Health and Biologicals, Inzymes ApS, Fermbox Bio, BRIG BIO, and Opes Diagnostics Limited.

Under a commercial agreement with Opes Diagnostics, a United Kingdom–based provider of diagnostic tools and reagents, Opes is using its relationships in Europe, Israel, and Asia to identify customers for Dyadic’s recombinant transferrin, growth factors, and related proteins used in serum‑free cell culture media. Dyadic retains the ability to sell directly and to work with additional partners globally.

Capital markets and listing status

Dyadic International, Inc. is incorporated in Delaware and its common stock is listed on the Nasdaq Capital Market under the symbol DYAI, as confirmed in multiple SEC filings. The company has used shelf registration statements and underwritten offerings to raise capital for working capital, product development, sales, and marketing. In 2025, Dyadic reported completing an underwritten public offering of common stock under an effective Form S‑3 shelf registration statement.

In 2025, Dyadic received Nasdaq deficiency notices related to the minimum Market Value of Listed Securities requirement and the minimum bid price requirement. Subsequent company disclosures state that, as of early October 2025, Dyadic had regained compliance with both the market value and minimum bid price listing standards, and that those deficiency matters were closed. A later notice dated December 19, 2025, however, indicated that the company again fell below the minimum bid price requirement, with a compliance period extending into 2026. These notices did not have an immediate effect on the listing of the company’s common stock, and Dyadic has stated its intention to monitor its stock price and evaluate options to regain compliance.

Corporate governance and shareholder matters

Dyadic holds annual meetings of shareholders where matters such as director elections, auditor ratification, and advisory votes on executive compensation are presented. At the 2025 Annual Meeting of Shareholders, proposals included the election of Class III directors, ratification of the company’s independent registered public accounting firm, and advisory votes on executive compensation and the frequency of such votes. Based on reported voting results, the board determined that advisory votes on executive compensation would occur annually.

Position within the biotechnology and manufacturing sector

Within the broader manufacturing sector, Dyadic is classified under All Other Basic Organic Chemical Manufacturing, reflecting its focus on biologically produced proteins and enzymes. The company positions its microbial platforms as tools for partners seeking to replace animal‑derived or traditional chemical inputs with fermentation‑derived biomolecules in life sciences, nutrition, and industrial applications.

According to its public statements, Dyadic’s strategy is to expand its portfolio of recombinant proteins, deepen collaborations across target markets, and use its C1 and Dapibus™ platforms, alongside CRISPR‑enabled strain engineering, to support scalable, non‑animal production of functional proteins and enzymes for commercial use.